Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Clinical trial NCT05426811 · UNKNOWN

Trial details

NCT number: NCT05426811
Sponsor: China Medical University, China
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Regorafenib Raltitrexed Colorectal Neoplasms Third-line Treatment

Start date: 2022-07-01
Primary completion: 2025-07-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.